Consilium Scientific

Don't miss our upcoming discussion panel, 'Inside Healthcare Investigations: Exposing the Realities of Clinical Research', in conversation with Deborah Cohen this Thursday at 5pm London Time! Sign up here: https://lnkd.in/dw6VNPt3

💡A recent article by Margaret McCartney explores how financial ties between the NHS and the pharmaceutical industry may influence clinical decisions, sometimes to the expense of evidence-based care. One example of this is the continued funding of atrial fibrillation screenings, which, against the recommendations of the National Screening Committee, continues to be promoted due to industry support. 🗣 This is a key issue Margaret discussed in her recent webinar with Consilium, where she spoke about the need for greater transparency and accountability in these relationships. You can watch the full recording of her talk here: https://lnkd.in/dykS3dHR We want to hear from you, the Consilium Scientific audience, thought about the article: ❓ How can healthcare systems maintain evidence-based practices while relying on pharmaceutical funding? ❓ What more can be done to protect patients from biased medical decisions influenced by industry money? Read the full article here: https://lnkd.in/dCukPdWe Follow Consilium on all platforms: https://lnkd.in/d9kagqEM #HealthcareTransparency #PharmaceuticalIndustry #ClinicalResearch #PatientCare #EvidenceBasedMedicine

🗣️ Join Consilium this Thursday in conversation with Deborah Cohen for an insightful conversation on investigative journalism in healthcare and clinical research! Deborah, an award-winning journalist and broadcaster, has exposed systemic challenges, driven policy change, and held powerful institutions accountable through investigations for the BMJ, BBC Newsnight, Panorama, and Channel 4 Dispatches. On Thursday, she will discuss how she combines rigorous data analysis with storytelling, utilising journalism to shed light on complicated health challenges that affect patients, practitioners and politicians worldwide. This is a unique opportunity to how complex healthcare topics are communicated to the public and on the global stage. 📅 Thursday, 31st October 🕒 5pm London Time 📍 Sign up here: https://lnkd.in/drtDUv_X #InvestigativeJournalism #HealthPolicy #HealthcareResearch

💡 This week, Consilium has been reading: Our UK-based audience has likely seen the reports that the Alzheimer’s drug Donanemab has been rejected by the National Institute of Health and Care Excellence (NICE) for use within the NHS. Despite being approved by the Medicines and Healthcare products Regulatory Agency, NICE determined that the drug’s high cost and modest benefits did not meet the criteria for widespread use within the NHS. This decision comes after a similar NICE recommendation on lecanemab in August, raising concerns about the accessibility of promising new treatments for patients. 🔍 What do you think? ❓ Was NICE’s decision the right call? How should healthcare systems like the NHS balance the cost and benefits of new treatments for widespread public use, especially in the context of age-associated diseases like Alzheimer's, where cases are predicted to rise dramatically in the coming years? ❓ How can we avoid creating a two-tier system for Alzheimer's patients, where those able to afford private treatment get access to treatments unavailable to those who rely on the NHS? We want to hear from you, the Consilium Scientific audience. Leave a comment on this post and let us know what you thought about the article. Read the full article here: https://lnkd.in/dU72nPnc We have recently hosted a number of panels discussing future advances in treating Alzheimer's, in which the use of amyloid-clearing drugs like Donanemab was explored in greater detail. You can find the discussions here: https://lnkd.in/dAqHqJ9s, https://lnkd.in/daT89qCK Make sure to follow Consilium on all of our platforms: https://lnkd.in/d9kagqEM #AlzheimersDisease #Lecanemab #NICE #PatientCare #Donanemab #AlzheimersResearch #NHS #PharmaceuticalInnovation #HealthcareCosts

Join Consilium for another discussion panel on Thursday, 31st October! ❓Inside Healthcare Investigations: Exposing the Realities of Clinical Research 📅 Thursday 31st October, 5pm London Time 🎫 Sign up here: https://lnkd.in/drtDUv_X Join Dr. Deborah Cohen, an award-winning investigative journalist and broadcaster, for an insightful conversation on uncovering critical issues in healthcare and clinical research. With her extensive experience in leading major investigations for The BMJ, BBC Newsnight, Panorama, and Channel 4 Dispatches, Dr. Cohen has exposed systemic challenges, driven policy change, and held powerful institutions accountable. In this session, she will share her approach to combining rigorous data analysis with storytelling, and discuss how investigative journalism can illuminate critical health and research issues that impact patients, practitioners, and policymakers alike. This is a unique opportunity to hear from a trailblazer who has transformed the way complex healthcare topics are communicated to the public and the global stage. In conversation with Deborah Cohen #ClincalResearch

🚨New video out now! Drugs for Alzheimer’s: Does Oncology Discovery Provide the Template?   Watch here: https://lnkd.in/d3j2J_3R Cancers and Alzheimer’s disease are the major health challenges of our era, with cases predicted to rise dramatically over the next decade. Both age-associated diseases share the characteristic of having multiple genes implicated in the onset and evolution of their complex pathologies. In the case of cancer, sequencing the DNA from human malignancies has revealed aberrantly activated genes (mutations and/or translocations) that drive malignancy. These present disease biomarkers and drug targets. Similarly, multiple genetic alterations and biomarkers have emerged for Alzheimer’s disease. Failure of early- and late-stage clinical drug candidates is a commonality between cancer and Alzheimer’s disease, reflecting the challenges of target validation and the inherent limitations of preclinical models. Should the past decades of biomarker identification, imaging, and drug discovery in oncology act as a robust model for securing advances in the diagnosis and therapy of Alzheimer’s disease? Does an understanding of cell death/apoptosis mechanisms provide opportunities in both diseases, where Alzheimer’s is characterized by post-mitotic cell death and cancer often by stubborn cell survival and replicative potential? Does the inflammation associated with both diseases point to the potential of novel immunological approaches? In this dialogue, experts in cancer pharmacology will be joined by experts in the molecular pathology and treatment of Alzheimer’s disease. They will discuss the question of whether progress in the diagnosis and treatment of cancer could be a template for making advances in Alzheimer’s disease. Speakers: Chair: Dr. Leeza Osipenko John Hickman George Perry Rudy Tanzi John Lazo

‘The current privileged focus on biopharmaceuticals is not a long-term, cost-effective approach to cancer control policy, unless it is complemented with public health strategies for cancer prevention’ is a statement recently published by the Lancet Oncology Commission. In January, Consilium hosted a panel discussion with expertise in cancer policy and treatment to discuss this statement and whether the pharmaceutical industry is too focused on drug discovery. Watch here: https://lnkd.in/dAaqZM84 If you enjoyed this talk, why not check out the Consilium Scientific Library? We have curated a selection of resources on topics including cancer and the pharmaceutical industry. 📖 Find books here: https://lnkd.in/dHTEHmHg 📽 Find films/podcasts here: https://lnkd.in/dY6fzWCB

Cancers and Alzheimer’s disease are the major health challenges of our era, with cases predicted to rise dramatically over the next decade. Both age-associated diseases share the characteristic of having multiple genes implicated in the onset and evolution of their complex pathologies. In the case of cancer, sequencing the DNA from human malignancies has revealed aberrantly activated genes (mutations and/or translocations) that drive malignancy. These present disease biomarkers and drug targets. Similarly, multiple genetic alterations and biomarkers have emerged for Alzheimer’s disease. Failure of early- and late-stage clinical drug candidates is a commonality between cancer and Alzheimer’s disease, reflecting the challenges of target validation and the inherent limitations of preclinical models. Should the past decades of biomarker identification, imaging, and drug discovery in oncology act as a robust model for securing advances in the diagnosis and therapy of Alzheimer’s disease? Does an understanding of cell death/apoptosis mechanisms provide opportunities in both diseases, where Alzheimer’s is characterized by post-mitotic cell death and cancer often by stubborn cell survival and replicative potential? Does the inflammation associated with both diseases point to the potential of novel immunological approaches? In this dialogue, experts in cancer pharmacology will be joined by experts in the molecular pathology and treatment of Alzheimer’s disease. They will discuss the question of whether progress in the diagnosis and treatment of cancer could be a template for making advances in Alzheimer’s disease.

Don't miss our upcoming discussion panel on Drugs for Alzheimer's: Does Oncology Discovery Provide the Template? this Thursday at 5pm London Time! Sign up here: https://lnkd.in/djCyPZc5

When researchers engage in questionable practices, the trustworthiness of their findings is threatened. By adopting open science practices, research becomes transparent and accountable and it becomes possible to verify whether trust in research findings is justified. In June 2023, Lex Bouter explored the magnitude of the issue as well as why researchers regularly engage in behaviours that harm the validity and trustworthiness of their work. Watch here: https://lnkd.in/eRA8MaMF If you enjoyed this talk, why not check out the Consilium Scientific Library? We have curated a selection of resources on topics including research integrity and transparency. 📖 Find books here: https://lnkd.in/dHTEHmHg 📽 Find films/podcasts here: https://lnkd.in/dY6fzWCB